NCT00245102 · STUDY IN CONTEXT

Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma

Draft scope assessment: narrower. Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm. Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.

Read the full study record and all posted results →

Linked outcomes

Measures are not ranked. Open each original source section for treatment groups, denominators, units and results.

primary · POSTED

A 5% response rate is considered not promising, a 20% response rate is considered promising. For each stratum, the response rate will be estimated and a confidence interval will be constructed.

Source null

→

Reported safety

Serious events are not the same as severe events. Compare the original safety groups and their at-risk populations.

Open the study safety table →

Quality of life and patient-reported measures

No linked quality-of-life measure is recorded for this setting and study.

Full draft applicability and source-link record

trial

release id: clinical-indications-draft-1
disease state id: ds-uterine-carcinosarcoma
nct id: NCT00245102
trial label: Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma
applicability: narrower
applicability note: Linked by condition-string match at the cancer-entity level. The study's eligibility - stage, biomarker, treatment line and prior therapy - has not been reconciled against this page's definition, so its population is narrower than this page in ways not yet recorded. The condition was transformed or resolved through the terminology hierarchy to reach this cancer type, so the link itself is a candidate a reviewer must confirm.
curation status: draft
reviewed by: Source null
reviewed at: Source null
created at: 2026-09-10T00:00:00Z
provenance class: registry-condition-search
discovery note: Found by searching ClinicalTrials.gov for this cancer type, restricted to studies that have posted results to the registry. No FDA notice, FDA label or NCI summary held by this site cites this study. Because the search asked for posted results, studies without posted results were never looked for, so their absence from this page means nothing.
outcome Count: 1
harms Count: 6
qol Count: 0

outcomes

release id
clinical-indications-draft-1
disease state id
ds-uterine-carcinosarcoma
nct id
NCT00245102
outcome key
om-0000
source section id
NCT00245102-om-0000
source outcome index
0
endpoint
Overall Response Rate Measured by Complete Response (CR) Rate and Partial Response (PR) Rate as Determined by RECIST
endpoint definition
A 5% response rate is considered not promising, a 20% response rate is considered promising. For each stratum, the response rate will be estimated and a confidence interval will be constructed.
time origin
Up to 4 weeks
analysis role
primary
reporting status
POSTED
data cutoff
Source null
population note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

arms

release id
clinical-indications-draft-1
disease state id
ds-uterine-carcinosarcoma
nct id
NCT00245102
outcome key
om-0000
arm key
OG000
arm label
Angiosarcoma
regimen
Sorafenib 400 mg PO BID
analyzed count
37
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00245102-om-0000#groups/OG000
release id
clinical-indications-draft-1
disease state id
ds-uterine-carcinosarcoma
nct id
NCT00245102
outcome key
om-0000
arm key
OG001
arm label
MPNST
regimen
Sorafenib 400 mg PO BID
analyzed count
12
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00245102-om-0000#groups/OG001
release id
clinical-indications-draft-1
disease state id
ds-uterine-carcinosarcoma
nct id
NCT00245102
outcome key
om-0000
arm key
OG002
arm label
Leiomyosarcoma
regimen
Sorafenib 400 mg PO BID
analyzed count
39
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00245102-om-0000#groups/OG002
release id
clinical-indications-draft-1
disease state id
ds-uterine-carcinosarcoma
nct id
NCT00245102
outcome key
om-0000
arm key
OG003
arm label
Undifferentiated Pleomorphic Sarcoma
regimen
Sorafenib 400 mg PO BID
analyzed count
10
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00245102-om-0000#groups/OG003
release id
clinical-indications-draft-1
disease state id
ds-uterine-carcinosarcoma
nct id
NCT00245102
outcome key
om-0000
arm key
OG004
arm label
Fibrosarcoma
regimen
Sorafenib 400 mg PO BID
analyzed count
5
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00245102-om-0000#groups/OG004
release id
clinical-indications-draft-1
disease state id
ds-uterine-carcinosarcoma
nct id
NCT00245102
outcome key
om-0000
arm key
OG005
arm label
Other Histology
regimen
Sorafenib 400 mg PO BID
analyzed count
19
analyzed unit
Participants
is comparator
Source null
source pointer
NCT00245102-om-0000#groups/OG005

harms

release id
clinical-indications-draft-1
disease state id
ds-uterine-carcinosarcoma
nct id
NCT00245102
harm key
EG000
source section id
NCT00245102-ae
event group key
EG000
event group label
Angiosarcoma
serious affected
13
serious at risk
44
other affected
36
other at risk
44
frequency threshold
5
collection period
Source null
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-uterine-carcinosarcoma
nct id
NCT00245102
harm key
EG001
source section id
NCT00245102-ae
event group key
EG001
event group label
MPNST
serious affected
7
serious at risk
16
other affected
12
other at risk
16
frequency threshold
5
collection period
Source null
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-uterine-carcinosarcoma
nct id
NCT00245102
harm key
EG002
source section id
NCT00245102-ae
event group key
EG002
event group label
Leiomyosarcoma
serious affected
7
serious at risk
46
other affected
40
other at risk
46
frequency threshold
5
collection period
Source null
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-uterine-carcinosarcoma
nct id
NCT00245102
harm key
EG003
source section id
NCT00245102-ae
event group key
EG003
event group label
Undifferentiated Pleomorphic Sarcoma
serious affected
9
serious at risk
13
other affected
10
other at risk
13
frequency threshold
5
collection period
Source null
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-uterine-carcinosarcoma
nct id
NCT00245102
harm key
EG004
source section id
NCT00245102-ae
event group key
EG004
event group label
Fibrosarcoma
serious affected
0
serious at risk
5
other affected
4
other at risk
5
frequency threshold
5
collection period
Source null
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z
release id
clinical-indications-draft-1
disease state id
ds-uterine-carcinosarcoma
nct id
NCT00245102
harm key
EG005
source section id
NCT00245102-ae
event group key
EG005
event group label
Other Histology
serious affected
5
serious at risk
23
other affected
21
other at risk
23
frequency threshold
5
collection period
Source null
event definition
Source null
undenominated note
Source null
curation status
draft
reviewed by
Source null
reviewed at
Source null
created at
2026-09-10T00:00:00Z

quality of life

setting source links

Preserved source evidence · Not medical advice